156 related articles for article (PubMed ID: 26846185)
1. Cost-utility analysis of deep brain stimulation surgery plus best medical therapy versus best medical therapy in patients with Parkinson's: Economic evaluation alongside the PD SURG trial.
McIntosh E; Gray A; Daniels J; Gill S; Ives N; Jenkinson C; Mitchell R; Pall H; Patel S; Quinn N; Rick C; Wheatley K; Williams A;
Mov Disord; 2016 Aug; 31(8):1173-82. PubMed ID: 26846185
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of neurostimulation in Parkinson's disease with early motor complications.
Dams J; Balzer-Geldsetzer M; Siebert U; Deuschl G; Schuepbach WM; Krack P; Timmermann L; Schnitzler A; Reese JP; Dodel R;
Mov Disord; 2016 Aug; 31(8):1183-91. PubMed ID: 27506638
[TBL] [Abstract][Full Text] [Related]
3. Economic Analysis of Deep Brain Stimulation in Parkinson Disease: Systematic Review of the Literature.
Becerra JE; Zorro O; Ruiz-Gaviria R; Castañeda-Cardona C; Otálora-Esteban M; Henao S; Navarrete S; Acevedo JC; Rosselli D
World Neurosurg; 2016 Sep; 93():44-9. PubMed ID: 27216925
[TBL] [Abstract][Full Text] [Related]
4. The cost-effectiveness of deep brain stimulation in combination with best medical therapy, versus best medical therapy alone, in advanced Parkinson's disease.
Eggington S; Valldeoriola F; Chaudhuri KR; Ashkan K; Annoni E; Deuschl G
J Neurol; 2014 Jan; 261(1):106-16. PubMed ID: 24158271
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Deep Brain Stimulation for Advanced Parkinson's Disease in the United States.
Pietzsch JB; Garner AM; Marks WJ
Neuromodulation; 2016 Oct; 19(7):689-697. PubMed ID: 27491661
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of subthalmic nucleus deep brain stimulation for the treatment of advanced Parkinson disease in Hong Kong: a prospective study.
Zhu XL; Chan DT; Lau CK; Poon WS; Mok VC; Chan AY; Wong LK; Yeung JH; Leung MC; Tang VY; Wong RK; Yeung C
World Neurosurg; 2014 Dec; 82(6):987-93. PubMed ID: 25175275
[TBL] [Abstract][Full Text] [Related]
7. Deep Brain Stimulation for Parkinson's Disease with Early Motor Complications: A UK Cost-Effectiveness Analysis.
Fundament T; Eldridge PR; Green AL; Whone AL; Taylor RS; Williams AC; Schuepbach WM
PLoS One; 2016; 11(7):e0159340. PubMed ID: 27441637
[TBL] [Abstract][Full Text] [Related]
8. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial.
Williams A; Gill S; Varma T; Jenkinson C; Quinn N; Mitchell R; Scott R; Ives N; Rick C; Daniels J; Patel S; Wheatley K;
Lancet Neurol; 2010 Jun; 9(6):581-91. PubMed ID: 20434403
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of deep brain stimulation in patients with Parkinson's disease.
Dams J; Siebert U; Bornschein B; Volkmann J; Deuschl G; Oertel WH; Dodel R; Reese JP
Mov Disord; 2013 Jun; 28(6):763-71. PubMed ID: 23576266
[TBL] [Abstract][Full Text] [Related]
10. [Review of the economic evidence on the use of deep brain stimulation in late stage Parkinson's disease].
Puig-Junoy J; Puig Peiró R
Neurologia; 2009 May; 24(4):220-9. PubMed ID: 19603291
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness Analysis of Deep Brain Stimulation in Patients with Parkinson's Disease in Japan.
Kawamoto Y; Mouri M; Taira T; Iseki H; Masamune K
World Neurosurg; 2016 May; 89():628-635.e1. PubMed ID: 26704203
[TBL] [Abstract][Full Text] [Related]
12. Protocol of a randomized open label multicentre trial comparing continuous intrajejunal levodopa infusion with deep brain stimulation in Parkinson's disease - the INfusion VErsus STimulation (INVEST) study.
van Poppelen D; Sisodia V; de Haan RJ; Dijkgraaf MGW; Schuurman PR; Geurtsen GJ; Berk AEM; de Bie RMA; Dijk JM
BMC Neurol; 2020 Jan; 20(1):40. PubMed ID: 32005175
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus.
Spottke EA; Volkmann J; Lorenz D; Krack P; Smala AM; Sturm V; Gerstner A; Berger K; Hellwig D; Deuschl G; Freund HJ; Oertel WH; Dodel RC
J Neurol; 2002 Jun; 249(6):759-66. PubMed ID: 12111311
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson's disease in the UK and Germany.
Walter E; Odin P
J Med Econ; 2015 Feb; 18(2):155-65. PubMed ID: 25348011
[TBL] [Abstract][Full Text] [Related]
15. Subthalamic Nucleus Deep Brain Stimulation May Reduce Medication Costs in Early Stage Parkinson's Disease.
Hacker ML; Currie AD; Molinari AL; Turchan M; Millan SM; Heusinkveld LE; Roach J; Konrad PE; Davis TL; Neimat JS; Phibbs FT; Hedera P; Byrne DW; Charles D
J Parkinsons Dis; 2016; 6(1):125-31. PubMed ID: 26967937
[TBL] [Abstract][Full Text] [Related]
16. Cost analysis of the treatments for patients with advanced Parkinson's disease: SCOPE study.
Valldeoriola F; Puig-Junoy J; Puig-Peiró R;
J Med Econ; 2013; 16(2):191-201. PubMed ID: 23035627
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness Analysis of Deep Brain Stimulation for Parkinson Disease in Taiwan.
Fann JC; Chang KC; Yen AM; Chen SL; Chiu SY; Chen HH; Liou HH
World Neurosurg; 2020 Jun; 138():e459-e468. PubMed ID: 32147563
[TBL] [Abstract][Full Text] [Related]
18. Clinical and economic results of bilateral subthalamic nucleus stimulation in Parkinson's disease.
Fraix V; Houeto JL; Lagrange C; Le Pen C; Krystkowiak P; Guehl D; Ardouin C; Welter ML; Maurel F; Defebvre L; Rougier A; Benabid AL; Mesnage V; Ligier M; Blond S; Burbaud P; Bioulac B; Destée A; Cornu P; Pollak P;
J Neurol Neurosurg Psychiatry; 2006 Apr; 77(4):443-9. PubMed ID: 16543519
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off.
Findley LJ; Lees A; Apajasalo M; Pitkänen A; Turunen H
Curr Med Res Opin; 2005 Jul; 21(7):1005-14. PubMed ID: 16004667
[TBL] [Abstract][Full Text] [Related]
20. Deep brain stimulation in the treatment of Parkinson's disease: a cost-effectiveness analysis.
Tomaszewski KJ; Holloway RG
Neurology; 2001 Aug; 57(4):663-71. PubMed ID: 11524476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
